Results 141 to 150 of about 676 (157)
Some of the next articles are maybe not open access.
Solriamfetol improves driving performance in patients with excessive sleepiness
The Brown University Psychopharmacology Update, 2022Adults with excessive daytime sleepiness associated with obstructive sleep apnea (OSA) who received solriamfetol showed improved driving performance relative to placebo in a two‐period crossover study. Solriamfetol resulted in reduced standard deviation of lateral position (SDLP) at 2 and 6 hours post‐dose.
openaire +1 more source
CNS Drugs, 2023
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA).
openaire +2 more sources
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA).
openaire +2 more sources
Galenus-Kandidat Solriamfetol - länger wach bei exzessiver Tagesschläfrigkeit
DNP - Der Neurologe & Psychiater, 2021openaire +1 more source
Effects of Solriamfetol on Driving Performance in Participants With Narcolepsy (2274)
Neurology, 2021Frederick Vinckenbosch +8 more
openaire +1 more source
Trial suggests effectiveness of solriamfetol for adult ADHD
The Brown University Psychopharmacology Update, 2023openaire +1 more source